Adhering to evidence-based surveillance guidelines will optimise the use of health care resources
Colorectal cancer (CRC) is the second most commonly diagnosed cancer in Australia in both men and women; there were about 17 000 new cases and more than 4000 deaths during 2017.1 It imposes a tremendous burden of disease, dominated by mortality rather than disability; in the 2011 Australian Burden of Disease Study, almost 86 000 years of life were lost because of CRC.2 The disorder is also a substantial economic burden; it costs more than $100 000 to treat one case of advanced CRC.3
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Australian Institute of Health and Welfare. National Bowel Cancer Screening Program: monitoring report 2017 (AIHW Cat. No. CAN 103). Canberra: AIHW, 2017.
- 2. Australian Institute of Health and Welfare. Australian Burden Of Disease Study: impact and causes of illness and death in Australia 2011 (AIHW Cat. No. BOD 4). Canberra: AIHW, 2016.
- 3. Australian Government Department of Health. National Bowel Cancer Screening Program: key statistics 2017. http://www.cancerscreening.gov.au/internet/screening/publishing.nsf/Content/key-statistics (viewed April 2018).
- 4. Zorzi M, Senore C, Turrin A, et al. Appropriateness of endoscopic surveillance recommendations in organised colorectal cancer screening programmes based on the faecal immunochemical test. Gut 2016; 65: 1822-1828.
- 5. Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993; 329: 1977-1981.
- 6. Australian Institute of Health and Welfare. Analysis of bowel cancer outcomes for the National Bowel Cancer Screening Program (AIHW Cat. No. CAN 87). Canberra: AIHW, 2014.
- 7. Honein-Abouhaidar GN, Kastner M, Vuong V, et al. Benefits and barriers to participation in colorectal cancer screening: a protocol for a systematic review and synthesis of qualitative studies. BMJ Open 2014; 4: e004508.
- 8. Knight JR, Kanotra S, Siameh S, et al. Understanding barriers to colorectal cancer screening in Kentucky. Prev Chronic Dis 2015; 12: E95.
- 9. Koo JH, You MY, Liu K, et al. Colorectal cancer screening practise is influenced by ethnicity of medical practitioner and patient. J Gastroenterol Hepatol 2012; 27: 390-396.
- 10. Schoen RE, Pinsky PF, Weissfeld JL, et al. Utilization of surveillance colonoscopy in community practice. Gastroenterology 2010; 138: 73-81.
- 11. van Heijningen EM, Lansdorp-Vogelaar I, Steyerberg EW, et al. Adherence to surveillance guidelines after removal of colorectal adenomas: a large, community-based study. Gut 2015; 64: 1584-1592.
- 12. Bampton PA, Sandford JJ, Young GP. Applying evidence-based guidelines improves use of colonoscopy resources in patients with a moderate risk of colorectal neoplasia. Med J Aust 2002; 176: 155-157. <MJA full text>
- 13. Cancer Council Australia Colonoscopy Surveillance Working Party. Clinical practice guidelines for surveillance colonoscopy — in adenoma follow-up; following curative resection of colorectal cancer; and for cancer surveillance in inflammatory bowel disease. Dec 2011. https://wiki.cancer.org.au/australiawiki/images/8/80/Colonoscopy_Surveillance_Guidelines_FINAL_version_NHMRC_approved_Dec2011.pdf (viewed Feb 2018).
- 14. Cancer Council Australia Surveillance Colonoscopy Guidelines Working Party. Draft clinical practice guidelines for surveillance colonoscopy. Sydney: Cancer Council Australia. Updated 3 Apr 2018. https://wiki.cancer.org.au/australiawiki/index.php?oldid=183316 (viewed Apr 2018).
- 15. Symonds EL, Simpson K, Coats M, et al. A nurse-led model at public academic hospitals maintains high adherence to colorectal cancer surveillance guidelines. Med J Aust 2018; 208: 492-496.
- 16. Patel N, Tong L, Ahn C, et al. Post-polypectomy guideline adherence: importance of belief in guidelines, not guideline knowledge or fear of missed cancer. Dig Dis Sci 2015; 60: 2937-2945.
No relevant disclosures.